According to The Fly, in a new note to investors yesterday, an analyst has provided a rating update for Endo International plc (ENL). The company recieved Buy from B.Riley FBR’s analyst David Buck.
Buck said:
“Endo posted 3Q18 results with revenues of C$745.5M, down 5.3% Y/Y versus our C$702.3M/ consensus C$692.8M. Branded Sterile Injectable sales of C$237.1M grew 17.4% Y/Y and topped our C$220.5M/consensus C$209.4M. Total generics of C$257.9M topped our C$233.0M although they missed (FactSet) consensus of C$281.4M with two outlier forecasts. Xiaflex brand grew 22% above our C$60.4M forecast. Endo’s 3Q18 results included gross margin of 66.9% which rose despite higher mix of lower-margin authorized generics. EPS of C$0.71 beat our C$0.56/$0.59 consensus. Endo raised its 2018 adjusted EPS guidance from C$2.50-$2.60 to C$2.65-$2.75 while adjusted EBITDA guidance moves from C$1.27B-$1.33B to C$1.32B-$1.34B. Endo raised 2018 revenue guidance from C$2.75B-$2.85B to C$2.87B-$2.92B.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 5.8% and a 52.1% success rate. Buck covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, Corcept Therapeutics Inc, and Spectrum Pharmaceuticals.
Read also: AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount
Endo International plc has an analyst consensus of Moderate Buy.
Based on Endo International plc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$226 million. In comparison, last year the company had a GAAP net loss of C$121 million.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.
